Pulse Biosciences, Inc. , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationtm (nano-PFA or nsPFAtm) technology, today announced plans to present at the upcoming TD Cowen ...

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir?the company's twice-yearly injectable HIV ...

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...

Allurion Technologies (ALUR) announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today ...

February 13, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the ...

NATICK, Mass., February 18, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity ...

Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...

Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...

In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...